RE:RE:Started a PositionMy thoughts as well Capharnaum. As for "top-line growth" its anything but "flatish" and we have a stellar record, over the past three years, something like 78 per cent on average per year I believe. And coming into this years topline growth, Analysts tracking WELL Health expect sales to touch $298 million in 2021 and rise by 63.4% to $488 million in 2022. So, WELL stock is trading at a forward price to sales multiple of less than two times which is really cheap.
And you have laid out the path to profitability quite nicely.